5.2 Safety evaluation In both clinical trials and real-world settings, tirzepatide has demonstrated a favorable safety and tolerability profile
However, these gastrointestinal activities are also the reason why subjects treated with GLP-1-based agents occasionally experience nausea
Its active compounds enhance GLP-1 secretion from intestinal L-cells while increasing GLP-1 receptor sensitivity, helping improve glucose metabolism, reduce lipid accumulation, and support weight management through activation of important metabolic pathways like AMPK-signaling
Researchers are already testing triple-agonist drugs, such as retatrutide, which target GLP-1, GIP and glucagon receptors
So what's the take-home message
Remarkably, there is evidence that GLP-1 agonists can enhance left ventricular ejection fraction, inotropy, coronary blood flow, cardiac output, and vascular endothelial function because of their cardiovascular effects and decrease overall cardiovascular event risks
